New collaboration to develop innovative chemistry for more efficient protein degrader molecules.

BioAscent is proud to announce its successful award of a Knowledge Transfer Partnership (KTP) with the Centre for Targeted Protein Degradation (CeTPD) at the School of Life Sciences, University of Dundee. This partnership will focus on the development and application of innovative chemistry methods to streamline the synthesis and testing of protein degrader molecules – a revolutionary area of therapeutic discovery.

This collaboration brings together BioAscent’s world-class pre-clinical drug discovery expertise with Dundee’s globally recognised leadership and experience in the field of targeted protein degradation. The initiative is poised to push new boundaries in drug discovery by enabling more efficient development and testing of innovative protein degraders, molecules that offer exciting potential for the treatment of currently untreatable diseases.

Duncan McArthur, Associate Director of Chemistry at BioAscent says: "We are thrilled to be working alongside the world-leading experts at Dundee’s CeTPD to drive the next phase of innovation in protein degradation. The collaboration is an outstanding example of public-private partnership, demonstrating how the world class excellence of Scottish industry and academia can work together to advance novel therapeutic approaches.”

Will Farnaby, Principal Investigator at CeTPD says: ‘‘We are excited to formalise this new partnership with BioAscent which, together with the support of Innovate UK, will enable a new degrader discovery platform approach with significant potential for accelerating drug discovery.’’

Allesio Ciulli, Director of CeTPD, adds: “This is an exciting newly established industry-academia collaboration that is poised to innovate much needed chemistry and boost our ability to find high-quality molecules more quickly and efficiently.

“I am delighted that our Centre has partnered with BioAscent on this journey, and I look forward to watching the progress and discoveries that will be enabled by this partnership, which will have broad applicability and scope to many of our programmes and the wider field beyond.”

By combining the latest advances in parallel synthesis and protein degrader chemistry, the partnership aims to accelerate the discovery of new treatments that could transform the drug development landscape.